For press inquiries click here to contact us.
Eikon Therapeutics
‘Changing the whole game of drug discovery’: Legendary R&D vet Roger Perlmutter leaps back into work as a biotech CEO
Bit Bio Limited
Meet The Company Reprogramming The Future Of Synthetic Biology
Tesseract Health, Inc.
Tesseract Health raises $80M in series B round
Inscripta
Inscripta CEO on Genomic Engineering (Podcast)
Inscripta
Inscripta Eyes Broader Genome Editing Reach with $150M Series E
Genomics PLC
Oxford’s Genomics Pushing the Boundaries of Personalized Medicine
SomaLogic
Proteomics company SomaLogic to chase $1.2B public valuation through SPAC deal
Inscripta
Inscripta closes $150M VC round, scores first commercial buyer of CRISPR gene editing platform
Inscripta
Having shipped its first benchtop gene editing devices, Inscripta draws another $150M from deep investor well
Please see important disclaimers in the Terms section.
